CAPTRUST Financial Advisors’s ADMA Biologics ADMA Stock Holding History

CAPTRUST Financial Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$793K	Buy	88,032 +24,455	+38%	+$386K	﹤0.01%	1727
2025 Q4	$1.16M	Buy	63,577 +28,746	+83%	+$484K	﹤0.01%	1409
2025 Q3	$511K	Sell	34,831 -611	-2%	-$10.5K	﹤0.01%	1804
2025 Q2	$645K	Buy	+35,442	New	+$723K	﹤0.01%	1576
2022 Q3	–	Sell	-40	Closed	–	–	2086
2022 Q2	$0	Buy	+40	New	+$79	﹤0.01%	4911
2021 Q3	–	Sell	-1,084	Closed	-$2K	–	4619
2021 Q2	$2K	Buy	+1,084	New	+$1.91K	﹤0.01%	4136

Other funds holding ADMA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

CAPTRUST Financial Advisors's ADMA Position: Q1 2026 in Review

CAPTRUST Financial Advisors increased its ADMA Biologics (ADMA) stake by 38% in Q1 2026, buying an estimated $386K and bringing the position to 88,032 shares worth $793K. The position accounts for ﹤0.01% of the portfolio, ranked #1727.

CAPTRUST Financial Advisors first reported a position in ADMA in Q2 2021 and has held it in 6 quarters since. The position peaked at $1.16M in Q4 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

CAPTRUST Financial Advisors held 88,032 shares of ADMA Biologics worth $793K as of Q1 2026.
CAPTRUST Financial Advisors bought 24,455 ADMA Biologics shares in Q1 2026, an estimated $386K.
ADMA Biologics made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q1 2026, its #1727 holding.
CAPTRUST Financial Advisors first reported a position in ADMA Biologics in Q2 2021 and has held it in 6 quarters since.
CAPTRUST Financial Advisors's ADMA Biologics position peaked at $1.16M in Q4 2025.
356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q1 2026, filed 15 May 2026.